Recruiting

Biological Samples

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07789119

Conditions

Urothelial Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

biospecimen Collection

Study Details

Brief summary:

To collect, process, store, and study biological samples and related clinical and imaging data from participants with known or suspected urothelial carcinoma or another related malignancy of the urinary tract.

Conditions

Urothelial Carcinoma

Study ID

NCT07789119

Start date

Sep 10, 2026

Status verified date

Sep, 2026

Completion date

Dec 31, 2038

Anticipated

Primary completion date

Dec 31, 2036

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Eligibility Criteria

Participants must meet all of the following criteria for enrollment:

1. Age 18 years or older at the time of consent.
2. Known or suspected urothelial carcinoma or other related malignancy of the urinary tract for which biospecimen and associated clinical data collection is relevant to the objectives of this protocol. This may include patients undergoing diagnostic evaluation for a lesion, mass, abnormal cytology, or other clinical finding concerning for malignancy.
3. Undergoing evaluation, treatment, surveillance, follow-up care, or clinically indicated procedures at The University of Texas M.D. Anderson Cancer Center, including Houston Area Locations.
4. Able to understand and personally provide informed consent.
5. Willing to allow prospective collection, banking, storage, and research use of biospecimens and associated clinical information as described in the informed consent document.

Exclusion Criteria

1. Age younger than 18 years.
2. Unable to understand the study information or unable to personally provide informed consent.
3. Declines participation.
4. No known or suspected urothelial carcinoma or other related malignancy of the urinary tract, and no clinical circumstance in which enrollment under this protocol is relevant to the study objectives.
5. Clinical, operational, or safety circumstances that make enrollment or research collection inappropriate or not feasible in the judgment of the treating clinical team or study investigators. Examples may include urgent clinical priorities, insufficient residual specimen after diagnostic needs are met, inability to safely obtain research specimens during a clinically indicated procedure, or inability to complete consent appropriately.
6. Prisoners or other populations requiring additional regulatory protections not specifically approved under this protocol.

Study Design

Enrollment

50000 participants

Anticipated

Interventions and Outcome Measures

Interventions

biospecimen Collection

biospecimen collection during routine care encounters or clinically indicated procedures

Primary outcome measure

  • Overall Survival [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts and Locations

Central contacts

Byron Lee, MD

713-792-3250BHLee@mdanderson.org

Locations

UT MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Bryon Lee, MD

713-792-3250BHLee@mdanderson.org

Principal Investigator:

Byron Lee, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Oct 5, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-06. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-10-05. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.